Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

Autor: Long, Georgina V *, *, Luke, Jason J *, Khattak, Muhammad A, de la Cruz Merino, Luis, Del Vecchio, Michele, Rutkowski, Piotr, Spagnolo, Francesco, Mackiewicz, Jacek, Chiarion-Sileni, Vanna, Kirkwood, John M, Robert, Caroline, Grob, Jean-Jacques, de Galitiis, Federica, Schadendorf, Dirk, Carlino, Matteo S, Mohr, Peter, Dummer, Reinhard, Gershenwald, Jeffrey E, Yoon, Charles H, Wu, Xi Lawrence, Fukunaga-Kalabis, Mizuho, Krepler, Clemens, Eggermont, Alexander M M, Ascierto, Paolo A
Zdroj: In The Lancet Oncology November 2022 23(11):1378-1388
Databáze: ScienceDirect